Personalis in the Spotlight at BTIG Investor Conference

FREMONT, CA – January 28, 2026 – As the management of Personalis, Inc. (Nasdaq: PSNL) prepares to meet with the investment community at the prestigious BTIG 13th Annual MedTech Conference on February 11, the company finds itself at a critical inflection point. Fresh off a 52-week stock high, the precision oncology firm is armed with powerful clinical data, a key Medicare reimbursement win, and a strategic commercial partnership. Yet, beneath the surface of this momentum lies a complex financial narrative of soaring clinical growth set against volatile biopharma revenues, setting the stage for a high-stakes presentation in Snowbird, Utah.

Investors and analysts will be watching closely as Personalis navigates this pivotal moment. The conference, a key venue for over 75 corporate management teams to engage directly with institutional investors, provides a crucial platform for the company to articulate its vision and address the pressing questions surrounding its path to sustainable growth and profitability.

The Double-Edged Sword of Growth

At the heart of the investor discussion will be Personalis's recent financial performance, which paints a picture of two distinct, diverging business segments. The company's core mission revolves around its NeXT Personal assay, a revolutionary liquid biopsy test for detecting minimal residual disease (MRD). The clinical adoption of this test has been nothing short of explosive.

In the third quarter of 2025, Personalis delivered 4,388 clinical tests, marking a staggering 364% increase year-over-year. This surge in clinical demand underscores a strong and growing appetite among oncologists for the company's ultra-sensitive cancer monitoring technology. This clinical revenue growth has been a consistent bright spot, climbing 400% year-over-year in the second quarter and setting new records throughout 2025.

However, this clinical success has been overshadowed by challenges in its biopharma services segment. Total revenue for Q3 2025 was $14.5 million, a significant 44% decrease from the same period in the prior year. The company attributed this decline primarily to logistical delays impacting the timing of samples for large projects with its biopharma partners. This volatility prompted Personalis to revise its full-year 2025 revenue guidance downward, from a range of $70-$80 million to $68-$73 million. Furthermore, gross margins have compressed, falling to 13.2% in Q3 2025 from 34% a year earlier. Investors will undoubtedly press management on its strategy to de-risk the biopharma segment and prevent its volatility from undermining the company's overall financial health.

Beyond the Biopsy: The Power of Ultra-Sensitive Detection

Despite the financial headwinds, the scientific and clinical foundation of Personalis appears stronger than ever. The company is a leader in the movement to transform cancer from a terminal diagnosis into a manageable chronic disease. Its core technology, the NeXT Personal assay, is at the forefront of this paradigm shift. It is a tumor-informed test, meaning it is personalized to each patient's unique cancer by sequencing their tumor to identify up to 1,800 genetic variants.

This personalized signature allows the test to achieve remarkable sensitivity, capable of detecting as little as one fragment of tumor DNA among a million healthy DNA fragments in a blood sample. This capability, which Personalis has validated in recent publications, is crucial for detecting minimal residual disease (MRD)—the trace amounts of cancer that can remain after surgery or treatment and lead to recurrence. By detecting MRD at the earliest possible timepoint, NeXT Personal empowers oncologists to make more informed decisions about adjuvant therapy, monitor treatment effectiveness in real-time, and potentially improve patient outcomes.

Recent clinical data has continued to validate this approach. Findings presented at the European Society of Medical Oncology (ESMO) Congress in September 2024 highlighted the test's strong performance in lung cancer, with 42% of crucial detections occurring in the ultra-sensitive range that only NeXT Personal enables. Further publications in December 2025 reinforced the assay's value in monitoring immunotherapy response across various solid tumors, solidifying its clinical utility.

Paving the Path to Market: Reimbursement and Partnerships

Translating groundbreaking technology into a viable business requires clearing two major hurdles: reimbursement and market access. Personalis has made significant strides on both fronts. In a landmark achievement, the company announced in November 2025 that it had secured Medicare coverage for its NeXT Personal Dx Breast MRD Recurrence Monitoring Test. This decision from the Centers for Medicare & Medicaid Services (CMS) is a critical validation of the test's clinical value and opens a significant revenue pathway, making it accessible to a large patient population.

Investors at the BTIG conference will be eager for an update on the company’s timeline for securing similar coverage for other cancer types, particularly lung cancer, where the clinical need is immense. Expanding reimbursement is fundamental to accelerating clinical revenue and achieving long-term profitability.

To drive market adoption, Personalis has also forged a key strategic partnership with Tempus AI, Inc. The collaboration, which began commercialization efforts in May 2024, leverages Tempus’s extensive commercial team and relationships with oncologists to promote NeXT Personal for breast and lung cancer, as well as for monitoring immunotherapy response. The success of this partnership is a critical factor in Personalis's ability to scale its clinical testing volume and compete effectively.

Navigating a Competitive Frontier

Personalis is not alone in its pursuit of the precision oncology market. The MRD testing space is becoming increasingly crowded, with several well-funded competitors. The total addressable market is estimated to be worth as much as $20 billion, attracting intense competition and innovation. Personalis will join other prominent life science firms at the BTIG conference, including Adaptive Biotechnologies and CareDx, each vying for investor attention in a dynamic sector.

In this environment, differentiation is key. Personalis management will likely emphasize its whole-genome sequencing approach and the superior sensitivity of NeXT Personal as its primary competitive advantages. The key question for investors is whether this technological edge, combined with its recent reimbursement wins and strategic partnerships, is sufficient to capture a significant share of the market.

As the management team takes the stage in Utah, they will be tasked with weaving these disparate threads—soaring clinical adoption, volatile legacy revenue, landmark reimbursement, and fierce competition—into a coherent and compelling narrative. The reception they receive from the discerning investors at the BTIG conference could very well set the tone for the company's valuation and strategic direction for the year ahead.